FDA Approves J&J Vision’s TECNIS Synergy, Synergy Toric II IOLs

Johnson & Johnson Vision received U.S. Food and Drug Administration (FDA) approval for its TECNIS Synergy and TECNIS Synergy Toric II IOLs, as well as Health Canada approval for the TECNIS Synergy Toric II IOLs. This next-gen PCIOL is built on the legacy TECNIS platform and delivers the widest range of continuous vision with the best near vision among leading PCIOLs,^3,4,6,7,8 superior contrast even in low-light conditions, and reduced spectacle wear.^1,2,3,4,8 In a company sponsored study, 9 out of 10 patients who received TECNIS Synergy IOL lenses didn’t need glasses after surgery.⁹
 
Cataracts lead the cause of preventable blindness, affecting over 100 million eyes worldwide,¹⁰ with over 90 percent of people developing them by age 65.¹¹ Cataract patients’ visual needs have drastically changed as digital devices become a crucial part of their daily lives.¹² The rapid switch to digital platforms increased demand for high-quality vision, from distance to intermediate to near, in every lighting condition.
 
“In the past 10 months of implanting the TECNIS Synergy IOL lens, I have seen excellent visual performance at all distances, and in a wide variety of lighting conditions, with most patients achieving freedom from glasses,” Dr. Ike Ahmed, Assistant Professor and Director of the Glaucoma and Advanced Anterior Surgical Fellowship, University of Toronto in Canada told the press. “Having used the TECNIS Toric II platform in other TECNIS lenses, I’m eager to use the TECNIS Synergy Toric II IOL in patients that require astigmatism correction.”
 
Over the past yesr, J&J Vision has earned North American clearance or approval for seven innovations to treat cataract patients, including the TECNIS Eyehance IOLs.
 
“The TECNIS Synergy IOL combines the best of extended depth of focus and multifocal technologies—to deliver the widest range of continuous vision with the best near vision among leading PCIOLs,^3,4,6,7 without the visual gaps caused by existing trifocal technology,” said Rajesh Rajpal, chief medical officer and global head of clinical and medical affairs at Johnson & Johnson Vision. “Additionally, we’ll offer TECNIS Synergy IOL on our new Toric II platform, when it launches later this year, to give surgeons the ability to address astigmatism at the time of surgery.”
 
TECNIS Synergy was launched in Europe and Asia Pacific in 2019, and is available in Latin America and Canada. The complete TECNIS Synergy IOL family will be available in North America this summer.
 
References
¹ TECNIS Synergy IOL with TECNIS Simplicity Delivery System DFU, Z311421E
² DOF2019OTH4002 – Weeber H. MTF of the TECNIS SynergyTM OptiBlue IOL, and other lens models. 27 Mar 2019.
³ DOF2019OTH4005 – Perez G. Simulated VA of the TECNIS SynergyTM IOL and AT Lisa Tri IOL. 5 May 2019.
⁴ DOF2019OTH4006 – Perez G. Simulated VA of the TECNIS SynergyTM IOL and FineVision IOL. 5 May 2019
⁵ DOF2020CT4015- (“Forte 1”): A Comparative Clinical Evaluation of a New TECNIS Presbyopia Correcting Intraocular Lens Against a PanOptix Intraocular Lens-SPECTACLE WEAR AND SATISFACTION RESULTS
⁶ TECNIS Multifocal 1-Piece IOL ZKB00 and ZLB00 DfU – US – Doc. #Z311328. Rev. A, 04/2018. REF2019CT4049.
⁷ DOF2020CT4014 – Forte 1: A Comparative Clinical Evaluation of a New TECNIS Presbyopia Correcting Intraocular Lens Against a PanOptix Intraocular Lens- Defocus Curves and Visual Acuity Results
⁸ TECNIS Symfony Extended Range of Vision IOL DfU – OUS – Doc. #Z311278. Rev. 01, 02/2018. REF2018CT4277.
⁹ DOF2020CT4015- (“Forte 1”): A Comparative Clinical Evaluation of a New TECNIS Presbyopia Correcting Intraocular Lens Against a PanOptix Intraocular Lens-SPECTACLE WEAR AND SATISFACTION RESULTS
¹⁰ World Health Organization. Blindness and Impairment. https://www.who.int/en/news-room/fact-sheets/detail/blindness-and-visual-impairment
¹¹ University of Michigan Kellogg Eye Center website. http://www.kellogg.umich.edu/patientcare/conditions/cataract.html. Accessed October 28, 2017. REF2016OTH0327
¹² Ofcom – Adults’ Media Use and Attitudes Report. 25 April 2018. REF2019CT4116.